Goodwin Procter LLP
At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
Generating articles
loading
Generating authors
loading
Goodwin Procter LLP
The FDA is hosting a virtual public workshop on September 19, 2022 on “Increasing the Efficiency of Biosimilar Development Programs...
Goodwin Procter LLP
Last week Samsung Bioepis and Organon announced FDA approval of their citrate-free, high-concentration (100 mg/ml) HUMIRA biosimilar, HADLIMA (adalimumab-bwwd).
Goodwin Procter LLP
On August 2, 2022, Coherus BioSciences, Inc. announced that the FDA approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar interchangeable with LUCENTIS...
Goodwin Procter LLP
Goodwin is actively seeking Associate attorneys to join its Intellectual Property (“IP”) Litigation team on both the East and West coast. Goodwin is looking for highly qualified, motivated,...
Goodwin Procter LLP
On Monday, Hikma announced a partnership with Celltrion to market YUFLYMA (CT-P17) in the Middle East and North Africa. CT-P17 is a high-concentration...
Goodwin Procter LLP
Science Advisors work alongside case teams to assist with the technical aspects of litigation.
Goodwin Procter LLP
The ACI’s 13th Annual Summit on Biosimilars & Innovator Biologics will be held on June 28 – 29, to contemplate the details of the rapidly changing landscape for biosimilars and innovator biologics.
Goodwin Procter LLP
Goodwin’s Digital Currency & Blockchain group to host a cocktail reception surrounding the conference NFT NYC, a large conference surrounding non-fungible tokens. To join us, please register here.
Goodwin Procter LLP
The annual Food & Drug Law (FDLI) conference will be held on June 14-15, bringing together experts from the federal government, industry, the private bar, non-profit, patient and consumer advocates...
Contact Details
New York
Email Website
The New York Times Building
620 Eighth Avenue
New York
United States
Telephone: 1-212-813 8800